Standardized broth microdilution antimicrobial susceptibility testing of Francisella tularensis subsp. holarctica strains from Europe and rare Francisella species

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2429-2433

  Georgi, Enrico ^a   Schacht, Erik ^a   Scholz, Holger C ^a   Splettstoesser, Wolf D ^a  

^a BUNDESWEHR INSTITUTE OF MICROBIOLOGY   (Germany)

Author keywords

F. hispaniensis; F. philomiragia; MICs; Treatment; Tularaemia

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PENICILLIN G; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRIA; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; CULTURE MEDIUM; EUROPE; FRANCE; FRANCISELLA; FRANCISELLA NOVICIDA; FRANCISELLA PHILOMIRAGIA; FRANCISELLA TULARENSIS; GERMANY; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ENVIRONMENTAL MICROBIOLOGY; EUROPE; FRANCISELLA; HUMANS; MICROBIAL SENSITIVITY TESTS; TULAREMIA;

EID: 84866604264     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks238     Document Type: Article

References (24)

1. Komitova R, Nenova R, Padeshki P et al. Tularemia in Bulgaria 2003-2004. J Infect Dev Ctries 2010; 4: 689-94.
2. Ugur KS, Ark N, Kilic S et al. Three cases of oropharyngeal tularemia in Turkey. Auris Nasus Larynx 2011; 38: 532-7.
3. Hauri AM, Hofstetter I, Seibold E et al. Investigating an airborne tularemia outbreak, Germany. Emerg Infect Dis 2010; 16: 238-43.
4. Tarnvik A, Priebe HS, Grunow R. Tularaemia in Europe: an epidemiological overview. Scand J Infect Dis 2004; 36: 350-5.
5. Maurin M, Pelloux I, Brion JP et al. Human tularemia in France, 2006-2010. Clin Infect Dis 2011; 53: e133-41.
6. WHO. WHO Guidelines on Tularaemia. 2007. http://www.cdc.gov/tularemia/resources/whotularemiamanual.pdf (8 February 2012, date last accessed).
7. Snowden J, Stovall S. Tularemia: retrospective review of 10 years' experience in Arkansas. Clin Pediatr (Phila) 2011; 50: 64-8.
8. Johansson A, Urich SK, Chu MC et al. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect Dis 2002; 34: 327-30.
9. Meric M, Willke A, Finke EJ et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS 2008; 116: 66-73.
10. Ikaheimo I, Syrjala H, Karhukorpi J et al. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000; 46: 287-90.
11. García del Blanco N, Gutierrez Martin CB, de la Puente Redondo VA et al. In vitro susceptibility of field isolates of Francisella tularensis subsp. holarctica recovered in Spain to several antimicrobial agents. Res Vet Sci 2004; 76: 195-8.
12. Valade E, Vaissaire J, Merens A et al. Susceptibility of 71 French isolates of Francisella tularensis subsp. holarctica to eight antibiotics and accuracy of the Etest method. J Antimicrob Chemother 2008; 62: 208-10.
13. Leelaporn A, Yongyod S, Limsrivanichakorn S et al. Emergence of Francisella novicida bacteremia, Thailand. Emerg Infect Dis 2008; 14: 1935-7.
14. Mailman TL, Schmidt MH. Francisella philomiragia adenitis and pulmonary nodules in a child with chronic granulomatous disease. Can J Infect Dis Med Microbiol 2005; 16: 245-8.
15. Yesilyurt M, Kilic S, Celebi B et al. Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey. J Antimicrob Chemother 2011; 66: 2588-92.
16. Tomaso H, Al Dahouk S, Hofer E et al. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains. Int J Antimicrob Agents 2005; 26: 279-84.
17. Kudelina RI, Olsufiev NG. Sensitivity to macrolide antibiotics and lincomycin in Francisella tularensis holarctica. J Hyg Epidemiol Microbiol Immunol 1980; 24: 84-91.
18. Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008; 52: 2276-8.
19. Splettstoesser WD, Seibold E, Zeman E et al. Rapid differentiation of Francisella species and subspecies by fluorescent in situ hybridization targeting the 23S rRNA. BMC Microbiol 2010; 10: 72.
20. Huber B, Escudero R, Busse HJ et al. Description of Francisella hispaniensis sp. nov., isolated from human blood, reclassification of Francisella novicida (Larson et al. 1955) Olsufiev et al. 1959 as Francisella tularensis subsp. novicida comb. nov. and emended description of the genus Francisella. Int J Syst Evol Microbiol 2010; 60: 1887-96.
21. Brown SD, Krisher K, Traczewski MM. Broth microdilution susceptibility testing of Francisella tularensis: quality control limits for nine antimicrobial agents and three standard quality control strains. J Clin Microbiol 2004; 42: 5877-80.
22. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria-Second Edition: Approved Guideline M45-A2. CLSI, Wayne, PA, USA, 2010.
23. Rodloff A, Bauer T, Ewig S et al. Susceptible, intermediate, and resistant-the intensity of antibiotic action. Dtsch Arztebl Int 2008; 105: 657-62.
24. Gestin B, Valade E, Thibault F et al. Phenotypic and genetic characterization of macrolide resistance in Francisella tularensis subsp. holarctica biovar I. J Antimicrob Chemother 2010; 65: 2359-67.